The Combined Use of Platelet-Rich Plasma Clot Releasate and Allogeneic Human Umbilical Cord Mesenchymal Stem Cells Rescue Glucocorticoid-Induced Osteonecrosis of the Femoral Head

Figure 3

In vitro effects of PRCR, UC-MSCs, and PRCR + UC-MSCs on the proliferation, migration, and capillary-like tube formation of DEX-treated HUVECs in the coculture systems (a) Cocultured with PRCR, UC-MSCs, and PRCR + UC-MSCs, the cell viability of DEX-treated HUVECs was examined by CCK-8 assay. These three treatment groups showed significant promotion of the HUVEC proliferation inhibited by DEX (). (b) Migration activities of DEX-treated HUVECs were examined by Transwell assay in different coculture conditions, followed by quantitative analysis. The treatment groups showed significant promotion of the HUVEC migration inhibited by DEX (). (c) Representative images of capillary-like tube formation in different coculture conditions, followed by quantitative analysis. The treatment groups showed significant promotion of the HUVEC angiogenesis differentiation inhibited by DEX (). (d) Western blotting was conducted to evaluate the VEGFA expression. Higher levels of VEGFA protein were detected in all treatment groups compared to the DEX group () (, ^#Comparisons between the DEX group and other groups, ; Comparisons between the two groups, ). CCK-8: cell counting kit-8 assay; VEGF: vascular endothelial growth factor; GADPH: glyceraldehyde-3-phosphate dehydrogenase; PRCR: platelet-rich plasma clot releasate; UC-MSCs: umbilical cord mesenchymal stem cells; DEX: dexamethasone; GADPH: glyceraldehyde-3-phosphate dehydrogenase.

(a)

(b)

(c)

(d)